Anika Therapeutics (ANIK) Tops Q2 EPS by 38c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.42 +1.56%
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.06, $0.38 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $40.37 million.
GUIDANCE:
Anika Therapeutics sees FY2023 revenue of $159.5-163 million, versus the consensus of $161.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
